Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03082209
Other study ID # M15-913
Secondary ID 2016-003887-37
Status Completed
Phase Phase 1
First received
Last updated
Start date March 20, 2017
Est. completion date January 21, 2022

Study information

Verified date December 2022
Source AbbVie
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously-treated solid tumors or hematologic malignancies. Only chemotherapy combination (ABBV-621 + FOLFIRI) enrolling participants with RAS-mutant CRC who have received one prior line of therapy is open for enrollment.


Recruitment information / eligibility

Status Completed
Enrollment 153
Est. completion date January 21, 2022
Est. primary completion date January 21, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Must have a diagnosis of a solid tumor (except primary brain tumors), acute myeloid leukemia (AML), or non-Hodgkin lymphoma (NHL); NHL may be of any subtype for Dose Escalation but is limited to diffuse large B-cell lymphoma (DLBCL) for those enrolled to the cohort evaluating the combination of ABBV-621 and venetoclax. Participants in the Dose Optimization solid tumor cohorts must have either colorectal cancer with documented KRAS mutations (as determined by local testing), or pancreatic cancer (irrespective of mutational status). Participants in the chemotherapy combination cohorts must have metastatic or advanced unresectable colorectal cancer with documented RAS mutations (as determined by local testing). - Participant in dose escalation or dose optimization cohort must have received at least one prior systemic therapy, and must have relapsed or progressed after, or failed to respond to any/all available effective therapy or therapies. - Participant in chemotherapy cohorts with CRC must have progressed after or failed to respond to initial systemic therapy. - Must have measurable disease (by Response Evaluation Criteria In Solid Tumors [RECIST] 1.1 for those with solid tumors; by Lugano classification for those with NHL), except those with AML, who must have histologically confirmed relapsed or refractory disease. - Must agree to provide the following samples for biomarker analysis: - All participants: archived tumor tissue (if available). - Participants in Dose Optimization (excluding AML): pre- and on-treatment fresh tissue biopsies. (Note: fresh tissue biopsies will be optional for participants with solid tumor or NHL in Dose Escalation and will be collected only if consent is provided) - All participants with AML: pre- and on-treatment bone marrow aspirates (BMA) - Participants in chemotherapy combination cohorts: participants must provide a fresh biopsy if an archival biopsy is not available - Participant in chemotherapy cohorts with CRC must have confirmed RAS mutation - Must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 - 2. Participants in chemotherapy combination cohorts must have ECOG Performance Score of 0 - 1. - Must have adequate hematologic, renal and hepatic function. Exclusion Criteria: - Participants with history of brain metastases who have not shown clinical and radiographic stable disease for at least 28 days after definitive therapy. In addition, any AML participant identified through cerebrospinal fluid (CSF) analysis, as having active central nervous system (CNS) disease, will be excluded. - Presence of primary hepatobiliary malignancy, including cholangiocarcinoma or hepatocellular carcinoma, gallbladder carcinoma, cancer of ampulla of Vater. - Receipt of any systemic anti-cancer agent, including investigational anti-cancer products, within 21 days prior to study drug administration or 3 half-lives, whichever is longer. - Participant with a history of cirrhosis or other indication of significant possible hepatic dysfunction. Note: Those with non-alcoholic steatohepatitis (NASH) should be discussed with the AbbVie TA MD before enrollment. - Participant with a positive diagnosis of hepatitis A, B, or C. - Dose Optimization combination cohorts only: Prior receipt, at any time, of a BCL-2 inhibitor - Dose Optimization combination cohorts only: Participant has received strong or moderate CYP3A inhibitors or inducers within 7 days prior to the initiation of study treatment. - Dose Optimization combination cohorts only: Participant has malabsorption syndrome or other condition that precludes enteral route of administration. - Dose Optimization combination cohorts only: Participant has promyelocytic leukemia (M3). - CRC chemotherapy cohort only: Participant with minor surgical procedures, such as fine needle aspirations or core biopsies, within 7 days prior to first dose of study drug are excluded. - Participants in CRC chemotherapy combination cohort only: cardiomyopathy, coronary/peripheral artery bypass graft, aneurysm or aneurysm repair, angioplasty, pulmonary hypertension, cerebrovascular accident or transient ischemic attack, within 1 year of first dose of study drug. - Chemotherapy combination CRC participants only: Prior receipt of an irinotecan-based chemotherapy. - Chemotherapy combination CRC participants only: Disease progression within 3-months of initiating first-line therapy. - Chemotherapy combination CRC participants only: history of Gilbert's syndrome or UG1T1A1 genotypes. - Chemotherapy combination with bevacizumab participants only: clinically significant conditions that may place the participant at higher risk with anti-angiogenic therapy.

Study Design


Intervention

Drug:
ABBV-621
Intravenous (IV)
Venetoclax
tablet, oral
Bevacizumab
IV infusion
FOLFIRI
IV infusion

Locations

Country Name City State
Japan National Cancer Center Hospital East /ID# 160596 Kashiwa-shi Chiba
Japan Yamagata University Hospital /ID# 200681 Yamagata-shi Yamagata
Netherlands Universitair Medisch Centrum Groningen /ID# 169748 Groningen
Netherlands Maastricht Universitair Medisch Centrum /ID# 214935 Maastricht
Netherlands Erasmus Medisch Centrum /ID# 160869 Rotterdam Zuid-Holland
Netherlands Universitair Medisch Centrum Utrecht /ID# 169747 Utrecht
Spain Hospital Universitario Vall d'Hebron /ID# 170809 Barcelona
Spain Hospital Universitario Fundacion Jimenez Diaz /ID# 200106 Madrid
Spain Hospital Universitario HM Sanchinarro /ID# 165136 Madrid
United States Univ Michigan Med Ctr /ID# 207134 Ann Arbor Michigan
United States The University of Chicago Medical Center /ID# 158030 Chicago Illinois
United States Ingalls Memorial Hosp /ID# 171221 Harvey Illinois
United States MD Anderson Cancer Center /ID# 202187 Houston Texas
United States Millennium Oncology /ID# 214981 Houston Texas
United States Medical College of Wisconsin /ID# 171152 Milwaukee Wisconsin
United States Vanderbilt University Medical Center /ID# 215000 Nashville Tennessee
United States Yale University /ID# 158029 New Haven Connecticut
United States Rhode Island Hospital /ID# 171157 Providence Rhode Island
United States South Texas Accelerated Research Therapeutics /ID# 160574 San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
AbbVie

Countries where clinical trial is conducted

United States,  Japan,  Netherlands,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) for ABBV-621 The MTD and/or RP2D of ABBV-621 will be determined during the dose escalation phase of the study of ABBV-621 Up to 21 days
Primary Area under the serum/plasma concentration time curve (AUC) of ABBV-621 Area under the serum/plasma concentration time curve (AUC) of ABBV-621. Up to 64 days
Primary Area under the serum/plasma concentration time curve (AUC) of Venetoclax Area under the serum/plasma concentration time curve (AUC) of venetoclax. Up to 64 days
Primary Maximum observed serum concentration (Cmax) of ABBV-621 Maximum observed serum concentration (Cmax) of ABBV-621. Up to 64 days
Primary Maximum observed serum concentration (Cmax) of Venetoclax Maximum observed serum concentration (Cmax) of venetoclax. Up to 64 days
Primary Time to Cmax (Tmax) of ABBV-621 Time to Cmax (Tmax) of ABBV-621. Up to 64 days
Primary Time to Cmax (Tmax) of Venetoclax Time to Cmax (Tmax) of ventoclax. Up to 64 days
Primary Terminal phase elimination rate constant (ß) for ABBV-621 Terminal phase elimination rate constant (ß) for ABBV-621. Up to 64 days
Primary Terminal phase elimination rate constant (ß) for Venetoclax Terminal phase elimination rate constant (ß) for venetoclax. Up to 64 days
Primary Terminal Phase Elimination Half-life (t1/2) of ABBV-621 in Plasma Terminal phase elimination half-life (t1/2) for ABBV-621. Up to 64 days
Primary Terminal Phase Elimination Half-life (t1/2) of Venetoclax in Plasma Terminal phase elimination half-life (t1/2) for venetoclax. Up to 64 days
Secondary QTcF Change from Baseline QT interval measurement corrected by Fridericia's formula (QTcF) mean change from baseline by dose level Up to 64 days
Secondary Number of Participants with Dose-limiting Toxicities (DLTs) Dose limiting toxicities for dose escalation purposes will be determined on events that occur during the first 21-day cycle (with protocol specified exceptions for AML participants). Up to 42 days after first day of study drug administration or 14 days after bone marrow biopsy showing < 5% blast count (whichever is later)
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients